Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Biomarkers in Immuno-oncology

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
Biomarker analyses from a phase I study of WNT974, a first-in-class Porcupine inhibitor, in patients (pts) with advanced solid tumors
Jordi Rodon
Vall d’Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors
John M Kirkwood
UPMC Hillman Cancer Center Melanoma and Skin Cancer Program, Pittsburgh, PA, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
Aung Naing
The University of Texas MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275
Padmanee Sharma
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Anthony W. Tolcher
START, San Antonio, TX, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors
Lillian L Siu
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma
Alexander C Huang
University Of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i
Reinhard Dummer
University Hospital Zürich, Zürich, Switzerland
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8